Insight Molecular Diagnostics (IMDX) Debt to Equity (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Debt to Equity for 6 consecutive years, with -$0.01 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 26.77% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.01 through Dec 2025, up 26.77% year-over-year, with the annual reading at -$0.01 for FY2025, 26.77% up from the prior year.
- Debt to Equity hit -$0.01 in Q4 2025 for Insight Molecular Diagnostics, up from -$0.11 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.63 in Q2 2025 to a low of -$0.11 in Q3 2025.
- Historically, Debt to Equity has averaged $0.05 across 5 years, with a median of $0.01 in 2022.
- Biggest five-year swings in Debt to Equity: soared 3456.76% in 2023 and later plummeted 281.62% in 2025.
- Year by year, Debt to Equity stood at $0.02 in 2021, then crashed by 85.07% to $0.0 in 2022, then skyrocketed by 3456.76% to $0.11 in 2023, then tumbled by 116.43% to -$0.02 in 2024, then grew by 26.77% to -$0.01 in 2025.
- Business Quant data shows Debt to Equity for IMDX at -$0.01 in Q4 2025, -$0.11 in Q3 2025, and $0.63 in Q2 2025.